An Early Phase 1 interventional study of Visual ROM augmentation and Visual ROM reduction in Stroke, sponsored by The Catholic University of America. Recruiting at 1 site in United States. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by The Catholic University of America · Early Phase 1, Interventional, and Basic science
Among 1,991 studies in Stroke with a site in United States — 394 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,991 studies in Stroke with a site in United States, this one is the 909th largest by planned enrollment of the 1,617 interventional ones, is one of 108 that started in 2025, is one of 126 in phase 1, reaches primary completion later than 135 of the 488 other live ones, and was the 1,935th registered.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
This study's planned enrollment of 30 is below the median of 49 across 6,024 interventional studies indexed under Stroke.
Browse Stroke studies →394 of the 1,991 studies in Stroke with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 1,415 Stroke studies recruiting now, 697 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →1,991 studies; the count open now beside each. This study's row is marked.
First in 1980; this study’s year is marked. 108 started in 2025.
Median enrollment 40 across the 1,617 interventional studies, 153 across the 363 observational. Of the 1,327 that completed or were terminated, 561 (42%) have results posted.
295 of 1,991 have an industry lead sponsor. The 10 most frequent:
The Catholic University of America is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
The Catholic University of America has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
166 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Among the 1,991 studies in Stroke with a site in United States, from their registry updates:
The following experiment will be conducted with 15 chronic stroke survivors and 15 control subjects. Subjects will perform hand movements in the virtual reality environment using a head-mounted display. Quest's onboard cameras allow real-time tracking of hand motion, estimating joint angles of the finger and the thumb. For each feedback manipulation condition (i.e., movement amplification or reduction), the estimated joint angles will be multiplied by a factor greater than 1 (amplification) or a factor smaller than 1 (reduction). Then the newly-estimated hand posture will be displayed in the VR environment. Subjects will be randomly assigned into two groups (A and B), who will receive the assistance in a different order. Subjects will perform finger extension under three conditions: no sensory modulation, movement visual feedback (VF) amplification, and movement VF reduction (error augmentation), while their movement muscle activation patterns are recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria for both groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Visual ROM augmentation · Device: Visual ROM reduction
Device: Visual ROM augmentation · Device: Visual ROM reduction
Finger joint ROM is amplified.
Visual feedback of finger joint ROM is reduced.
Joint range of motion (ROM)
range of motion of individual finger joints under each condition, measured by embedded cameras that digitize individual finger segments
Time frame: Periprocedural
Muscle activation
Activation level of hand muscles will be measured using surface EMG electrodes attached to the major hand muscles including extensor digitorum communis, flexor digitorum superficialis, and first dorsal interosseous.
Time frame: Periprocedural
Plan to share: No — The investigators do not plan to share IPD but the de-identified data will be shared.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 12 months is below that.
Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Catholic University of America